Sex-Dependent Improvement in Survival of Parkinson's Disease Patients.

Tomi Kuusimäki,Heli Salminen‐Mankonen,Olli Carpén,Samu Kurki,Valtteri Kaasinen,Jussi O.T. Sipilä

doi:10.1002/mdc3.12954

Abstract

Advances in the treatment of Parkinson's disease (PD) and changes in general life expectancy may have improved survival in patients with PD. The objective of this study was to investigate recent trends in PD mortality. In total, 1521 patients with PD in local and national registries were followed for 11 years (2006-2016) from diagnosis until exit date or death, and the causes of death were recorded. The survival of men with PD improved during the follow-up period, but no change was observed in women (2-year postdiagnosis survival in men, 79.0%-86.3%, P = 0.03; 2-year postdiagnosis survival in women, 82.8%-87.5%, P = 0.42). Pneumonia was the most common immediate cause of death. The survival of men with PD has improved in Finland without a similar change in women. Because changes in treatment likely affect both sexes similarly, the results may reflect the decreasing sex gap in life expectancy. This phenomenon will likely increase the already high male-to-female prevalence ratio of PD.

Highlights

Advances in the treatment of Parkinson’s disease (PD) and changes in general life expectancy may have improved survival in patients with PD
The overall survival (OS) of male patients with PD increased during the follow-up period (P = 0.03), but no change was observed in women (P = 0.42; Table 1, Fig. 1)
The results demonstrate that the mortality of male Finnish patients with PD has decreased during a period of 11 years

Summary

Introduction

Advances in the treatment of Parkinson’s disease (PD) and changes in general life expectancy may have improved survival in patients with PD. Methods: In total, 1521 patients with PD in local and national registries were followed for 11 years (2006–2016) from diagnosis until exit date or death, and the causes of death were recorded. Results: The survival of men with PD improved during the follow-up period, but no change was observed in women (2-year postdiagnosis survival in men, 79.0%–86.3%, P = 0.03; 2-year postdiagnosis survival in women, 82.8%–87.5%, P = 0.42). Because changes in treatment likely affect both sexes the results may reflect the decreasing sex gap in life expectancy. This phenomenon will likely increase the already high male-to-female prevalence ratio of PD

Objectives

Methods

Results

Conclusion